Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MAGE-A3 TCR-T cells in metastatic cancer
NCT02111850Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2014
- Primary completion
- Mar 2021
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-MAGE-A3-DP4 T cell receptor peripheral blood lymphocytes in metastatic cancer, melanoma, renal cell carcinoma (RCC), urothelial carcinoma (UC), breast cancer, sponsored by National Cancer Institute. Started Feb 2014; status: completed.
02
Drugs
anti-MAGE-A3-DP4 T cell receptor peripheral blood lymphocytes
03
Conditions
metastatic cancermelanomarenal cell carcinoma (RCC)urothelial carcinoma (UC)breast cancer
Beyond the preview
Go deeper on NCT02111850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02111850.